1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Technology appraisal guidance [TA261] Published date: 25 July 2012

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

6 Recommendations for further research

6 Recommendations for further research

6.1 Further research on the clinical effectiveness of rivaroxaban compared with LMWH in patients with active cancer should be conducted.

  • National Institute for Health and Care Excellence (NICE)

  • Next